MIMEDX GROUP INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MDXG$3.37+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows – For the years ended
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net income (loss) from continuing operations | $41,998 | $67,439 | $(19,953) |
| Adjustments to reconcile net income (loss) from continuing operations to net cash flows provided by (used in) operating activities of continuing operations: | |||
| Share-based compensation | 16,933 | 16,959 | 11,328 |
| Deferred income tax provision | 12,472 | (37,802) | — |
| Shares received in settlement of litigation | (9,300) | — | — |
| Amortization of intangible assets | 3,762 | 762 | 701 |
| Depreciation | 2,279 | 2,665 | 3,345 |
| Loss on extinguishment of debt | 1,401 | — | — |
| Non-cash lease expenses | 1,310 | 1,268 | 1,259 |
| Credit loss expense | 595 | 1,449 | 2,820 |
| Other | 1,112 | 613 | 542 |
| Increase (decrease) in cash resulting from changes in: | |||
| Accounts receivable | (2,552) | (12,237) | (5,937) |
| Inventory | (2,357) | (7,838) | (1,794) |
| Prepaid expenses | 606 | (283) | (1,371) |
| Other assets | (958) | 1,535 | (333) |
| Accounts payable | (1,410) | 783 | 839 |
| Accrued compensation | 2,896 | 1,829 | (1,859) |
| Accrued expenses | (789) | (1,708) | 2,366 |
| Other liabilities | (870) | (497) | 75 |
| Net cash flows provided by (used in) operating activities of continuing operations | 67,128 | 34,937 | (7,972) |
| Net cash flows used in operating activities of discontinued operations | (930) | (8,162) | (9,921) |
| Net cash flows provided by (used in) operating activities | 66,198 | 26,775 | (17,893) |
| Cash flows from investing activities: | |||
| Purchases of equipment | (1,683) | (1,987) | (1,514) |
| Cash paid for acquisitions | (7,862) | — | — |
| Other | (38) | (168) | (1,146) |
| Net cash flows used in investing activities | (9,583) | (2,155) | (2,660) |
| Cash flows from financing activities: | |||
| Proceeds from Citizens Revolving Credit Facility | 30,000 | — | — |
| Proceeds from Citizens Term Loan Facility | 19,783 | — | — |
| Prepayment premium on Hayfin term loan | (500) | — | — |
| Deferred financing cost | (1,101) | — | — |
| Repayment of Hayfin term loan | (50,000) | — | — |
| Repayment of Citizens Revolving Credit Facility | (30,000) | — | — |
| Principal payments on Citizens Term Loan Facility | (1,000) | — | — |
| Proceeds from exercise of stock options | 1,397 | 997 | 651 |
| Stock repurchased for tax withholdings on vesting of restricted stock | (2,641) | — | (1,190) |
| Repurchase of Series B Preferred Shares | — | (9,515) | — |
| Other | (137) | (52) | (41) |
| Net cash flows used in financing activities | (34,199) | (8,570) | (580) |
F- 6
| Net change in cash | 22,416 | 16,050 | (21,133) |
|---|---|---|---|
| Cash and cash equivalents, beginning of period | 82,000 | 65,950 | 87,083 |
| Cash and cash equivalents, end of period | $104,416 | $82,000 | $65,950 |
F- 7
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.